Let’s work together to build a future
 without dementia.

Cognitive decline and dementia affect millions of people around the world.

people affected with dementia worldwide
0 m
Americans are living with Alzheimer's disease
0 m
is spent annually on care for Americans with dementia
$ 0 b

Memory loss comes first.

Sensitive detection of memory changes is key to clinical trial success, early intervention, improving outcomes, and enhancing quality of life.

Augnition Labs offers innovative AI-powered digital assessment tools that enable rapid, reliable, and objective detection of memory decline years in advance.

About
Team
Science
News

Contact Us

For inquiries please contact us at info@augnitionlabs.com

Copyright © 2023 Augnition Labs, LLC.

Financial Compliance Information

Marco Peters, Ph.D.

Co-Founder and Scientific Advisor

Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. He built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, pain, and schizophrenia. He currently serves as vice president and head of translational science at Longboard Pharmaceuticals. Peters built the departments of Neurobiology and Behavioral Pharmacology, and managed target identification, in vivo pharmacology, and lead optimization at Dart Neuroscience. His work contributed to the advancement of multiple compounds into clinical development, and led to a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Peters has a M.Sc. in Biochemistry from the Freie Universität Berlin, Germany and a PhD in Neuroscience from the University of London, UK. He conducted postdoctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).